SCHEMBL5348265

SCHEMBL5348265

CCOC(=O)CNc1ccc(C(F)(F)F)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.69
IDH1 O75874 3/20 0.61
NPSR1 Q6W5P4 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 1/20 0.50
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
EPHX2 P34913 1/20 0.46
FPR2 P25090 1/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 1/20 0.44
PPID Q08752 1/20 0.44
GAA P10253 1/20 0.44
FFAR1 O14842 1/20 0.43
PPARG P37231 1/20 0.43
LMNA P02545 1/20 0.43
CA12 O43570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14625975 0.88 POLB (0.55) POLBIDH1NPSR1L3MBTL1MAPT
SCHEMBL23310334 0.86 POLB (0.62) POLBIDH1L3MBTL1NPC1RAB9A
SCHEMBL10704732 0.86 POLB (0.62) POLBIDH1NPSR1L3MBTL1NPC1
SCHEMBL5112169 0.85 POLB (0.50) POLBIDH1NPSR1L3MBTL1NPC1
SCHEMBL1441875 0.84 POLB (0.57) POLBIDH1NPSR1L3MBTL1NPC1
Hydrochloric Acid SCHEMBL5773679 0.84 POLB (0.49) POLBIDH1NPSR1L3MBTL1NPC1
SCHEMBL27350327 0.84 MEN1 (0.65) POLBIDH1NPSR1NPC1RAB9A
SCHEMBL696485 0.82 IDH1 (0.62) POLBIDH1NPSR1L3MBTL1SMN1; SMN2
SCHEMBL5445479 0.82 POLB (0.66) POLBIDH1NPSR1SMN1; SMN2MAPT
SCHEMBL3052619 0.82 POLB (1.00) POLBIDH1L3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4393909-A1 HYDANTOIN COMPOUND AND MEDICAL USE THEREOF Harbin Medisan Pharmaceutical Co., LTD. (CN) 2024-07-03 EP disclosed
US-7160902-B2 Amide derivatives and methods of their use ADOLOR CORPORATION (US) 2007-01-09 US disclosed
US-7160902-B2 Amide derivatives and methods of their use ADOLOR CORPORATION (US) 2007-01-09 US disclosed
WO-2005049564-A1 AMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-06-02 WO disclosed
US-20050107355-A1 Amide derivatives and methods of their use CUBIST PHARMACEUTICALS, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107355-A1 Amide derivatives and methods of their use HRH2, SLC10A2, ALPI POLB 2823/4885IDH1 3777/4885NPSR1 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.